Prognostic indicator predicts immune responses and therapeutic response in hepatocellular carcinoma, suggesting new treatment strategies.
The newly prognostic BMRGs signature can be used as a prognostic indicator to predict the potential progression trajectory and therapeutic response in HCC, which may also provide sensible recommendations for immunotherapy and the selection of chemotherapeutic agents. Our findings provided a promising insight into BMRGs in HCC and a personalized prediction tool for prognosis and immune responses in patients.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: